mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials

We evaluated if standard hormonal therapy (HT) could be improved by the addition of mammalian target of rapamycin inhibitors (mTOR-I) in metastatic luminal breast cancer. A meta-analysis on 4 phase II-III randomized clinical trials was performed. Pooled hazard ratio (HR) for progression free surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Rotundo, Maria Saveria, Galeano, Teresa, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053632/
https://www.ncbi.nlm.nih.gov/pubmed/26895472
http://dx.doi.org/10.18632/oncotarget.7446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053632/
https://www.ncbi.nlm.nih.gov/pubmed/26895472
http://dx.doi.org/10.18632/oncotarget.7446

Ejemplares similares